SFI
BDTX icon

Susquehanna Fundamental Investments’s Black Diamond Therapeutics BDTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-109,277
Closed -$169K – 749
2025
Q1 		$169K Buy
109,277
+34,374
+46% +$72.1K ﹤0.01% 1010
2024
Q4 		$160K Buy
+74,903
New +$215K ﹤0.01% 1023
2024
Q2 		– Sell
-16,218
Closed -$82.2K – 935
2024
Q1 		$82.2K Buy
+16,218
New +$65.4K ﹤0.01% 657

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna Fundamental Investments's BDTX Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Black Diamond Therapeutics (BDTX) in Q2 2025, closing a stake of 109,277 shares — an estimated $169K sold.

Susquehanna Fundamental Investments first reported a position in BDTX in Q1 2024 and held it in 3 quarters. The position peaked at $169K in Q1 2025. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2025.

  • Susquehanna Fundamental Investments reported no remaining Black Diamond Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 109,277 Black Diamond Therapeutics shares in Q2 2025, an estimated $169K.
  • Susquehanna Fundamental Investments first reported a position in Black Diamond Therapeutics in Q1 2024 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Black Diamond Therapeutics position peaked at $169K in Q1 2025.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.